Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Patients with type 2 diabetes at high cardiovascular risk received either once-weekly semaglutide, a glucagon-like peptide 1 analogue, or placebo. The rate of a first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke was significantly lower with semaglutide. Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. 1 Recently, trials evaluating a sodium–glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in patients with type 2 diabetes who were at high risk for cardiovascular events. 2 , 3 Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4 is currently in development but not yet approved for the treatment of type 2 diabetes. Regulatory guidance specifies the need to establish the cardiovascular safety of new therapies for type . . .